美国生物医药产业竞争力分析与启示

进入生物经济时代以来,以生物医药产业为代表的生物技术产业正在引领人类新一波技术产业革命。我国针对生物医药产业作出的战略部署已经取得了明显成效,但与美国等生物医药强国相比仍有较大的竞争差距。采用波特钻石模型构建了生物医药产业国际竞争力理论分析框架,以美国为例分析其生物医药产业在要素状况、企业结构和竞争、需求条件、相关及支持性产业、政府和发展机会六个方面的竞争优势,并基于此提出了我国发展生物医药产业的政策建议,从而为我国生物医药产业发展提供政策参考。     

A scoping review of guidelines for the use of race,ethnicity, and ancestry reveals widespread consensus but also points of ongoing disagreement

1. Download : Download high-res image (198KB)
2. Download : Download full-size image

     

Isolation and properties of ovine [1-pyroglutamic acid]-β-lipoprotein

A new form of ovine β-lipotropin has been isolated by partition chromatography on agarose gel. All the evidence is consistent with the conclusion that its structure is identical to that of ovine β-lipotropin with the exception that the glutamic acid residue in position 1 was replaced by a pyroglutamic acid residue. Its lipolytic activity in isolated rabbit fat cells was about one-half that of β-lipotropin.     

The effects of non-crop habitat on spotted wing drosophila (Drosophila suzukii) abundance in fruit systems: A meta-analysis

1. Drosophila suzukii (SWD) poses a threat to soft and stone fruit globally. SWD inhabits non-crop areas adjacent to farms from where it moves into crops to cause damage. Effective IPM control strategies, considering both the crop and non-crop area, are needed to control this economically important pest.
2. We conducted a meta-analysis to quantify the impacts of different non-crop habitats around fruit farms on SWD populations, comparing abundance of SWD trapped in crop and non-crop habitats.
3. Overall, SWD abundance was greater in non-crop habitats than in cropped areas and this difference was greatest in farms adjacent to woodland, or field margins containing known SWD host plants.
4. The difference in SWD abundance between crop and non-crop habitats was not affected by crop type but was greatest in the winter months and in conventional compared to organic farms, indicating conventional approaches can reduce relative SWD abundance.
5. Drosophila suzukii overwinter in non-crop habitats which provide refuge outside the cropping season. However, certain habitats support greater relative abundance of SWD than others and this is also affected by farm management. We discuss what these findings mean for effective control of SWD.

     

Guidelines for the design and conduct of human clinical trials on ingestion-time differences – chronopharmacology and chronotherapy – of hypertension medications

ABSTRACT

Current hypertension guidelines fail to provide a recommendation on when-to-treat, thus disregarding relevant circadian rhythms that regulate blood pressure (BP) level and 24 h patterning and medication pharmacokinetics and pharmacodynamics. The ideal purpose of ingestion-time (chronopharmacology, i.e. biological rhythm-dependent effects on the kinetics and dynamics of medications, and chronotherapy, i.e. the timing of pharmaceutical and other treatments to optimize efficacy and safety) trials should be to explore the potential impact of endogenous circadian rhythms on the effects of medications. Such investigations and outcome trials mandate adherence to the basic standards of human chronobiology research. In-depth review of the more than 150 human hypertension pharmacology and therapeutic trials published since 1974 that address the differential impact of upon-waking/morning versus at-bedtime/evening schedule of treatment reveals diverse protocols of sometimes suboptimal or defective design and conduct. Many have been “time-of-day,” i.e. morning versus evening, rather than circadian-time-based, and some relied on wake-time office BP rather than around-the-clock ambulatory BP measurements (ABPM). Additionally, most past studies have been of too small sample size and thus statistically underpowered. As of yet, there has been no consensual agreement on the proper design, methods and conduct of such trials. This Position Statement recommends ingestion-time hypertension trials to follow minimum guidelines: (i) Recruitment of participants should be restricted to hypertensive individuals diagnosed according to ABPM diagnostic thresholds and of a comparable activity/sleep routine. (ii) Tested treatment-times should be selected according to internal biological time, expressed by the awakening and bed times of the sleep/wake cycle. (iii) ABPM should be the primary or sole method of BP assessment. (iv) The minimum-required features for analysis of the ABPM-determined 24 h BP pattern ought to be the asleep (not “nighttime”) BP mean and sleep-time relative BP decline, calculated in reference to the activity/rest cycle per individual. (v) ABPM-obtained BP means should be derived by the so-called adjusted calculation procedure, not by inaccurate arithmetic averages. (vi) ABPM should be performed with validated and calibrated devices at least hourly throughout two or more consecutive 24 h periods (48 h in total) to achieve the highest reproducibility of mean wake-time, sleep-time and 48 h BP values plus the reliable classification of dipping status. (vii) Calculation of minimum required sample size in adherence with proper statistical methods must be provided. (viii) Hypertension chronopharmacology and chronotherapy trials should preferably be randomized double-blind, randomized open-label with blinded-endpoint, or crossover in design, the latter with sufficient washout period between tested treatment-time regimens.